Seoul-Sana
Today, South Korea began the third phase of clinical trials of the (GPP510) vaccine against the Corona virus.
And Yonhap news agency quoted the South Korean company (SK BioScience), which developed the vaccine, as saying that “the third stage began today, nearly 3 weeks after the approval of the Ministry of Food and Drug Safety in Seoul, to become (GPP510) the first local vaccine candidate in South Korea to enter South Korea. The last phase of clinical trials.
Clinical trials will be conducted simultaneously in different countries by giving the candidate vaccine to about 3,000 participants, and it will be compared with the anti-Corona vaccines produced by AstraZeneca to determine the degree of safety and ability to generate immunity.
